+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bicyclic Peptide Drug Conjugates Market - Global Forecast 2025-2030- Product Image
Bicyclic Peptide Drug Conjugates Market - Global Forecast 2025-2030- Product Image
Sale

Bicyclic Peptide Drug Conjugates Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6079157
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Bicyclic peptide drug conjugates are redefining targeted therapy development, offering decision-makers new strategies for overcoming resistance and delivering precision treatment in complex disease landscapes. As the sector evolves, innovations in molecular design, manufacturing, and global policy are influencing market trajectories and shaping competitive differentiation.

Market Snapshot: Bicyclic Peptide Drug Conjugate Market

The global market for bicyclic peptide drug conjugates is witnessing notable growth, propelled by advances in automated peptide synthesis, stable scaffold structures, and structure-based drug design. Strategic partnerships among pharmaceutical and biotech entities are enhancing the pathway from discovery to preclinical validation, while streamlined regulatory mechanisms support innovative bioconjugate therapies’ swift entry into clinical pipelines. Private and public funding, together with expanding investment in specialized technologies, support ongoing pipeline expansion and accelerate progression toward commercialization.

Scope & Segmentation

This report delivers detailed segmentation insights, regional perspectives, and company analysis, providing comprehensive coverage for senior executives shaping development and commercialization in this field.

  • Therapeutic Areas: Immunology (autoimmune disorders, inflammatory diseases), infectious diseases (bacterial, parasitic, viral), and oncology (hematologic malignancies including leukemia, lymphoma, and solid tumors such as breast and lung cancer).
  • Payload Types: Cytostatic agents (small molecule inhibitors), cytotoxic agents (auristatins, maytansinoids).
  • Linker Chemistry: Cleavable (enzyme, glutathione, and pH sensitive) and non-cleavable (oxime, thioether) structures.
  • Route of Administration: Intravenous and subcutaneous modalities.
  • Applications: Diagnostics (biomarker detection, imaging) and therapeutics.
  • End Users: Hospitals, research institutes (including academic laboratories and contract research organizations), specialty clinics.
  • Regional Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including the United Kingdom, Germany, France, South Africa, UAE, more), and Asia-Pacific (China, India, Japan, Australia, Southeast Asian countries).
  • Key Technologies: Advanced automated peptide synthesis, structure-based design, high throughput screening, and computational modeling platforms.
  • Featured Companies: Pfizer Inc., Bicycle Therapeutics Ltd., PeptiDream Co., Ltd., Amgen Inc., Merck & Co., Inc., Roche Holding AG, GlaxoSmithKline plc, Johnson & Johnson, Affilogic SAS, Sutro Biopharma, Inc.

Key Takeaways for Decision-Makers

  • Technological innovation is transforming drug conjugate research, reducing time-to-proof-of-concept and enabling precise targeting of previously refractory disease pathways.
  • Convergent advances in linker and payload design deliver enhanced efficacy and safety profiles, with distinct agent classes now applied across immunological, infectious, and oncological indications.
  • Collaborative ecosystems—uniting academic expertise, contract development, and leading pharmaceutical organizations—are central to rapid candidate selection, trial deployment, and regulatory engagement.
  • Global variation in regulatory requirements, reimbursement structures, and infrastructure investment creates differentiated adoption opportunities and operational hurdles across regions.
  • The evolving intellectual property landscape encourages proprietary advances in conjugate scaffolds and linker chemistries, influencing competitive positioning and licensing activity in the sector.

Tariff Impact: Navigating New Cost Structures

With the introduction of revised United States tariff policies in 2025, procurement dynamics for bicyclic peptide drug conjugates have shifted. Elevated costs for imported reagents and specialty raw materials have resulted, prompting organizations to shift towards regional sourcing and dual supplier strategies. Enhanced inventory management and closer budget alignment with clinical milestones help mitigate expense increases, while real-time tariff monitoring supports greater operational resilience.

Methodology & Data Sources

This report is based on extensive secondary research, a wide review of literature, patents, and regulatory sources, complemented by structured interviews with industry practitioners and expert validation panels. Data triangulation and robust quality checks were applied to ensure accuracy and practical value for strategic planning in the bicyclic peptide drug conjugate market.

Why This Report Matters

  • Offers a strategic overview to inform investment, partnership, and R&D priorities in a rapidly evolving therapeutic sector.
  • Delivers actionable insights on segmentation, operational risk, and innovation (including tariff and policy response strategies) for alignment with current and future market needs.

Conclusion

Bicyclic peptide drug conjugates present compelling opportunities for advancing patient care and targeted therapy innovation. Stakeholders leveraging robust segmentation, flexible sourcing, and next-generation technology will be best positioned for sustainable success as the market landscape evolves.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging site-specific conjugation methods enhancing bicyclic peptide drug conjugate stability and efficacy
5.2. FDA breakthrough therapy designations accelerating clinical development of novel bicyclic peptide ADCs in solid tumors
5.3. Integration of cleavable linkers responsive to tumor microenvironment in bicyclic peptide drug conjugates
5.4. Collaborative partnerships between biotech startups and pharma giants driving innovation in bicyclic peptide ADC pipelines
5.5. Investment surge in next-generation bicyclic peptide scaffolds optimizing binding affinity and tumor targeting specificity
5.6. Emergence of multi-valent bicyclic peptide conjugates enabling simultaneous engagement of multiple tumor antigens for improved efficacy
5.7. Advancements in in vivo imaging techniques facilitating real-time tracking of bicyclic peptide drug conjugate biodistribution
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bicyclic Peptide Drug Conjugates Market, by Therapeutic Area
8.1. Introduction
8.2. Immunology
8.2.1. Autoimmune Disorders
8.2.2. Inflammatory Diseases
8.3. Infectious Diseases
8.3.1. Bacterial Infections
8.3.2. Parasitic Infections
8.3.3. Viral Infections
8.4. Oncology
8.4.1. Hematologic Malignancies
8.4.1.1. Leukemia
8.4.1.2. Lymphoma
8.4.2. Solid Tumors
8.4.2.1. Breast Cancer
8.4.2.2. Lung Cancer
9. Bicyclic Peptide Drug Conjugates Market, by Payload Type
9.1. Introduction
9.2. Cytostatic Agents
9.3. Cytotoxic Agents
9.3.1. Auristatins
9.3.2. Maytansinoids
10. Bicyclic Peptide Drug Conjugates Market, by Linker Chemistry
10.1. Introduction
10.2. Cleavable
10.2.1. Enzyme Sensitive
10.2.2. Glutathione Sensitive
10.2.3. PH Sensitive
10.3. Non Cleavable
10.3.1. Oxime
10.3.2. Thioether
11. Bicyclic Peptide Drug Conjugates Market, by Route Administration
11.1. Introduction
11.2. Intravenous
11.3. Subcutaneous
12. Bicyclic Peptide Drug Conjugates Market, by Application
12.1. Introduction
12.2. Diagnostic
12.2.1. Biomarker Detection
12.2.2. Imaging
12.3. Therapeutic
13. Bicyclic Peptide Drug Conjugates Market, by End User
13.1. Introduction
13.2. Hospitals
13.3. Research Institutes
13.3.1. Academic Labs
13.3.2. Contract Research Organizations
13.4. Specialty Clinics
14. Americas Bicyclic Peptide Drug Conjugates Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Bicyclic Peptide Drug Conjugates Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Bicyclic Peptide Drug Conjugates Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Pfizer Inc.
17.3.2. Bicycle Therapeutics Ltd.
17.3.3. PeptiDream Co., Ltd.
17.3.4. Amgen Inc.
17.3.5. Merck & Co., Inc.
17.3.6. Roche Holding AG
17.3.7. GlaxoSmithKline plc
17.3.8. Johnson & Johnson
17.3.9. Affilogic SAS
17.3.10. Sutro Biopharma, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. BICYCLIC PEPTIDE DRUG CONJUGATES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 6. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY PAYLOAD TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY PAYLOAD TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LINKER CHEMISTRY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LINKER CHEMISTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BICYCLIC PEPTIDE DRUG CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. BICYCLIC PEPTIDE DRUG CONJUGATES MARKET: RESEARCHAI
FIGURE 28. BICYCLIC PEPTIDE DRUG CONJUGATES MARKET: RESEARCHSTATISTICS
FIGURE 29. BICYCLIC PEPTIDE DRUG CONJUGATES MARKET: RESEARCHCONTACTS
FIGURE 30. BICYCLIC PEPTIDE DRUG CONJUGATES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY IMMUNOLOGY, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CYTOSTATIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CYTOSTATIC AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CYTOTOXIC AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY AURISTATINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY AURISTATINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY MAYTANSINOIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY MAYTANSINOIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CYTOTOXIC AGENTS, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LINKER CHEMISTRY, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LINKER CHEMISTRY, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CLEAVABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CLEAVABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ENZYME SENSITIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ENZYME SENSITIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY GLUTATHIONE SENSITIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY GLUTATHIONE SENSITIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY PH SENSITIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY PH SENSITIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY NON CLEAVABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY NON CLEAVABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY OXIME, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY OXIME, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY THIOETHER, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY THIOETHER, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY NON CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY NON CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY BIOMARKER DETECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY BIOMARKER DETECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY IMAGING, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ACADEMIC LABS, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ACADEMIC LABS, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY IMMUNOLOGY, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CYTOTOXIC AGENTS, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LINKER CHEMISTRY, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LINKER CHEMISTRY, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY NON CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY NON CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY IMMUNOLOGY, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CYTOTOXIC AGENTS, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LINKER CHEMISTRY, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LINKER CHEMISTRY, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY NON CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY NON CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 181. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 182. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 183. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
TABLE 184. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY IMMUNOLOGY, 2025-2030 (USD MILLION)
TABLE 185. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 186. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 187. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 188. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 189. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 190. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 191. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 192. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 193. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 194. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 195. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2024 (USD MILLION)
TABLE 196. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CYTOTOXIC AGENTS, 2025-2030 (USD MILLION)
TABLE 197. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LINKER CHEMISTRY, 2018-2024 (USD MILLION)
TABLE 198. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LINKER CHEMISTRY, 2025-2030 (USD MILLION)
TABLE 199. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 200. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 201. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY NON CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 202. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY NON CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 203. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 204. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 205. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 206. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 207. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 208. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 209. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 212. CANADA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 213. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 214. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 215. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
TABLE 216. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY IMMUNOLOGY, 2025-2030 (USD MILLION)
TABLE 217. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 218. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 219. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 220. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 221. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 222. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 223. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 224. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 225. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 226. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 227. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2024 (USD MILLION)
TABLE 228. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CYTOTOXIC AGENTS, 2025-2030 (USD MILLION)
TABLE 229. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LINKER CHEMISTRY, 2018-2024 (USD MILLION)
TABLE 230. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LINKER CHEMISTRY, 2025-2030 (USD MILLION)
TABLE 231. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 232. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 233. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY NON CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 234. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY NON CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 235. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 236. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 237. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 238. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 239. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 240. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 241. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 244. MEXICO BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY IMMUNOLOGY, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 255. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 256. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 257. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 258. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CYTOTOXIC AGENTS, 2025-2030 (USD MILLION)
TABLE 261. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LINKER CHEMISTRY, 2018-2024 (USD MILLION)
TABLE 262. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LINKER CHEMISTRY, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY NON CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY NON CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 276. BRAZIL BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 277. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 278. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 279. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
TABLE 280. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY IMMUNOLOGY, 2025-2030 (USD MILLION)
TABLE 281. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 282. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 283. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 284. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 285. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
TABLE 286. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2030 (USD MILLION)
TABLE 287. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
TABLE 288. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY SOLID TUMORS, 2025-2030 (USD MILLION)
TABLE 289. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY PAYLOAD TYPE, 2018-2024 (USD MILLION)
TABLE 290. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY PAYLOAD TYPE, 2025-2030 (USD MILLION)
TABLE 291. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CYTOTOXIC AGENTS, 2018-2024 (USD MILLION)
TABLE 292. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CYTOTOXIC AGENTS, 2025-2030 (USD MILLION)
TABLE 293. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LINKER CHEMISTRY, 2018-2024 (USD MILLION)
TABLE 294. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY LINKER CHEMISTRY, 2025-2030 (USD MILLION)
TABLE 295. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 296. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY CLEAVABLE, 2025-2030 (USD MILLION)
TABLE 297. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY NON CLEAVABLE, 2018-2024 (USD MILLION)
TABLE 298. ARGENTINA BICYCLIC PEPTIDE DRUG CONJUGATES MARKET SIZE, BY NON CLEAVABLE, 2025-2030 (USD MILLION)
T

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Bicyclic Peptide Drug Conjugates market report include:
  • Pfizer Inc.
  • Bicycle Therapeutics Ltd.
  • PeptiDream Co., Ltd.
  • Amgen Inc.
  • Merck & Co., Inc.
  • Roche Holding AG
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Affilogic SAS
  • Sutro Biopharma, Inc.

Related Topics

Related Reports

Waterproofing Chemical Market - Global Forecast 2025-2030 - Product Image

Waterproofing Chemical Market - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Cell Membrane Fluorescent Probe Market - Global Forecast 2025-2030 - Product Image

Cell Membrane Fluorescent Probe Market - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Peptide Conjugates Service Market - Global Forecast 2025-2030 - Product Image

Peptide Conjugates Service Market - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Antibody-siRNA Drug Conjugates Market - Global Forecast 2025-2030 - Product Image

Antibody-siRNA Drug Conjugates Market - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Organic Chemistry, International Adaptation. Edition No. 4 - Product Image

Organic Chemistry, International Adaptation. Edition No. 4

  • Book
  • 1392 Pages
  • Global
Copyright © 2002-2025 Research and Markets. All Rights Reserved.